Relutrigine

SCN2A- and SCN8A-related developmental and epileptic encephalopathies

Manufacturer: Praxis Precision Medicines
Regulatory submission: NDA submitted in early 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Product comparison

1 evidence topic · 1 source

Preclinical comparison: protective index in mouse seizure and locomotor assays

Compound	Protective index
PRAX-562	“16.2”
Lamotrigine	“4.7”
Carbamazepine	“5.9”

Direct clinical comparison with another active antiseizure medication

No evidence found.